Researchers use a new way to deliver CRISPR/Cas9 to tumors in mice, wiping out the cancer.
View Full Profile
Learn about our Editorial Policies.
Special stealth liposomes with a polyethylene glycol (PEG) coating that serves to hide the liposomes from the immune system are injected into mice with tumors (1). There, the PEG covering spontaneously falls off (2), allowing the liposomes to merge with cells and deliver CRISPR-Cas9 gene editing machinery (3). The system is designed to slice the powerful oncogene E7 (4), triggering apoptosis (5) and wiping out the tumors.
Read the full story.
After earning a bachelor’s degree in biology and neuroscience from Williams College, Rachael spent two years studying the tiny C. elegans worm as a lab tech at Massachusetts General Hospital/Harvard University. She then returned to school to get a master’s degree in environmental studies from Brown University, and subsequently worked as an intern at Scientific American, Discover magazine, and the Annals of Improbable Research, the originators of the yearly Ig Nobel prizes. She now freelances for both scientific and lay publications, and loves telling the stories behind the science. Find her at rachaelgorman.com or on Instagram @
Memory-enhancing neural networks may also drive involuntary musical loops in the brain.
View this Issue
In this webinar, Brian Hie will discuss Evo2, a state-of-the-art genomic foundation model capable of generalist prediction and design tasks across DNA, RNA, and proteins.
In this webinar, learn how scientists use advanced human brain models to uncover treatment strategies for complex neurological conditions.
Manufacturing cell-based therapeutics requires a robust workflow from start to finish.
Modern DNA synthesis platforms empower researchers to explore the molecular world, from next-generation sequencing to cell and gene therapy development.
This new product line is specifically engineered to meet the rigorous demands of immunology research, vaccine development, animal studies, cell and gene therapy, and therapeutic protein manufacturing.
New fluidics and clog detection systems further simplify operation and reduce instrument downtime
Researchers aim to discover dominant subtypes of plasmablasts initiating from the MMR vaccine in order to develop neutralizing antibody candidate therapies
Study identifies new metrics to enhance scRNA-seq based virtual cell modelling
